TSCAN THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.76 USD | +1.62% |
|
+19.27% | +49.14% |
| Apr. 19 | TScan Therapeutics Closes $150.1 Million Securities Offering | MT |
| Apr. 17 | TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants | MT |
Chart calendar TScan Therapeutics, Inc.
e3974b00566b8225.D_rwc8uvKmK1VM9B0ZxPdPfx1X8JoXNgvFprHI9N8bM.dqKvAKzeRAP3Drtw4-w_RYGru0ljxhAq12Iyc80fucI9kpYwrONGIMxjng~1eb49ed2d7ebc813b9eb138373a4aa0e
Upcoming events on TScan Therapeutics, Inc.
Past events on TScan Therapeutics, Inc.
| 2024-04-09 02:15 pm | Needham Healthcare Conference |
| 2024-04-08 04:30 pm | American Association for Cancer Research Meeting - Abstract No:CT151 |
| 2024-04-08 04:30 pm | American Association for Cancer Research Meeting - Abstract No:CT170 |
| 2024-03-06 09:10 am | TD Cowen Health Care Conference - Panel |
| 2024-03-06 07:00 am | Q4 2023 Earnings Release |
| 2024-02-26 08:00 am | Investor Meeting - Key Opinion Leader |
| 2024-02-23 09:45 am | American Society for Transplantation and Cellular Therapy and Center for International Blood and Mar |
| 2023-12-11 08:00 am | American Society of Hematology Meeting |
| 2023-12-09 08:30 pm | American Society of Hematology Meeting - Abstract Number:2090 |
| 2023-11-09 07:00 am | Q3 2023 Earnings Release |
| 2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 682 |
| 2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 364 |
| 2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 390 |
| 2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 376 |
| 2023-11-03 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 357 |
| 2023-11-03 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number: 709 |
| 2023-09-13 01:30 pm | H.C. Wainwright Global Investment Conference |
| 2023-09-12 04:55 pm | Morgan Stanley Global Healthcare Conference |
| 2023-08-10 07:00 am | Q2 2023 Earnings Release |
| 2023-06-13 08:00 am | Annual General Meeting |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 10,1 11,3 -10.4% | 13,5 13,9 -2.58% | 21,0 16,9 24.84% | 17,6 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -42,8 -50,8 15.81% | -56,9 -63,0 9.58% | -82,9 -86,1 3.69% | -108 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -48,6 -50,4 3.58% | -66,6 -65,3 -2.11% | -93,5 -98,1 4.71% | -108 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -48,6 -49,1 1% | -66,2 -65,3 -1.39% | -89,2 -94,3 5.36% | -99,2 |
|
Net income Million USD | Released Forecast Spread | -26,1 | -48,6 -49,1 1% | -66,2 -64,8 -2.21% | -89,2 -96,1 7.16% | -103 |
|
EPS USD | Released Forecast Spread | -3,48 | -4,17 -9,67 56.85% | -2,75 -2,39 -15.22% | -1,36 -1,43 5.06% | -1,03 |
| Announcement Date | 19/03/21 | 09/03/22 | 08/03/23 | 06/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2,85 3,47 -17.67% | 3,02 2,76 9.64% | 4,06 3,00 35.03% | 3,36 3,93 -14.43% | 3,10 4,10 -24.44% | 6,80 4,30 58.08% | 3,15 4,37 -28.03% | 3,89 4,45 -12.66% | 7,21 3,45 108.77% | 4,30 | 4,42 | 4,58 | 4,71 | 2,50 |
|
EBIT Million USD | Released Forecast Spread | -14,2 -16,3 12.85% | -16,2 -17,1 5.72% | -15,2 -18,0 15.44% | -16,6 -17,6 5.94% | -18,6 -17,3 -7.99% | -22,7 -18,0 -26.41% | -24,6 -24,9 1.24% | -24,7 -23,9 -3.7% | -21,4 -26,0 17.78% | -25,4 | -26,4 | -27,6 | -28,6 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -14,2 -15,8 10.16% | -16,2 -17,3 6.49% | -15,1 -18,5 18.49% | -16,2 -18,5 12.11% | -18,7 -17,6 -6.61% | -22,6 -16,8 -34.41% | -24,0 -24,2 0.58% | -23,0 -23,3 1.35% | -19,6 -24,7 20.48% | -23,9 | -24,3 | -25,3 | -25,7 | |
|
Net income Million USD | Released Forecast Spread | -14,2 -15,8 10.16% | -16,2 -17,1 5.6% | -15,1 -18,0 16.26% | -16,2 -17,6 7.82% | -18,7 -17,2 -8.92% | -22,6 -18,0 -25.43% | -24,0 -24,6 2.07% | -23,0 -23,4 1.55% | -19,6 -24,7 20.57% | -24,5 | -25,3 | -26,4 | -27,3 | |
|
EPS USD | Released Forecast Spread | -0,59 -0,68 12.59% | -0,67 -0,72 6.94% | -0,63 -0,76 16.74% | -0,67 -0,72 6.51% | -0,78 -0,70 -10.9% | -0,93 -0,75 -24.83% | -0,51 -0,76 32.6% | -0,24 -0,43 43.75% | -0,11 -0,26 57.69% | -0,25 | -0,24 | -0,26 | -0,27 | |
| Announcement Date | 09/03/22 | 09/05/22 | 10/08/22 | 09/11/22 | 08/03/23 | 10/05/23 | 10/08/23 | 09/11/23 | 06/03/24 | - | - | - | - | - |
| Today 06:30 am | MODERNA, INC.: Q1 2024 Earnings Release |
| Today 07:00 am | BLUEPRINT MEDICINES CORPORATION: Q1 2024 Earnings Release |
| Today 07:00 am | KYMERA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| Today 07:00 am | IQVIA HOLDINGS INC.: Q1 2024 Earnings Release |
| Today 08:00 am | ALNYLAM PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 2024-05-05 | REVOLUTION MEDICINES, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-05 | SYNDAX PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-06 | FORTREA HOLDINGS INC.: Q1 2024 Earnings Release |
| 2024-05-06 | VERVE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 2024-05-06 | OLEMA PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
Past sector events for TScan Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- TCRX Stock
- Calendar TScan Therapeutics, Inc.
